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Abstract
Background: Breast cancer is a remarkably heterogeneous disease. Luminal, basal-like, ‘‘normal-like’’, and ERBB2+ subgroups
were identified and were shown to have different prognoses. The mechanisms underlying this heterogeneity are poorly
understood. In our study, we explored the role of cellular differentiation and senescence as a potential cause of heterogeneity.
Methodology/Principal Findings: A panel of breast cancer cell lines, isogenic clones, and breast tumors were used. Based on
their ability to generate senescent progeny under low-density clonogenic conditions, we classified breast cancer cell lines as
senescent cell progenitor (SCP) and immortalcell progenitor (ICP) subtypes.AllSCPcell lines expressedestrogen receptor (ER).
Loss of ER expression combined with the accumulation of p21
Cip1 correlated with senescence in these cell lines. p21
Cip1
knockdown, estrogen-mediated ER activation or ectopic ER overexpression protected cells against senescence. In contrast,
tamoxifen triggered a robust senescence response. As ER expression has been linked to luminal differentiation, we compared
the differentiation status of SCP and ICP cell lines using stem/progenitor, luminal, and myoepithelial markers. The SCP cells
produced CD24+ or ER+ luminal-like and ASMA+ myoepithelial-like progeny, in addition to CD44+ stem/progenitor-like cells.
In contrast, ICP cell lines acted as differentiation-defective stem/progenitor cells. Some ICP cell lines generated only CD44+/
CD24-/ER-/ASMA- progenitor/stem-like cells, and others also produced CD24+/ER- luminal-like, but not ASMA+ myoepithelial-
like cells. Furthermore, gene expression profiles clustered SCP cell lines with luminal A and ‘‘normal-like’’ tumors, and ICP cell
lines with luminal B and basal-like tumors. The ICP cells displayed higher tumorigenicity in immunodeficient mice.
Conclusions/Significance: Luminal A and ‘‘normal-like’’ breast cancer cell lines were able to generate luminal-like and
myoepithelial-like progeny undergoing senescence arrest. In contrast, luminal B/basal-like cell lines acted as stem/
progenitor cells with defective differentiation capacities. Our findings suggest that the malignancy of breast tumors is
directly correlated with stem/progenitor phenotypes and poor differentiation potential.
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Introduction
Human breast tumors are heterogeneous, both in their
pathology and in their molecular profiles. Gene expression
analyses classify breast tumors into distinct subtypes, such as
luminal A, luminal B, ERBB2-positive (ERBB2+) and basal-like
[1,2,3]. The prognosis and therapeutic response of each subtype is
different. Luminal A cancers are mostly estrogen receptor-a-
positive (ER+) and sensitive to anti-estrogen therapy, with the best
metastasis-free and overall survival rates. Luminal B tumors have
an incomplete anti-estrogen response and lower survival rates.
Basal-like and ERBB2+ tumors are ER- and display the worst
survival rates [2,3]. The patterns of genetic changes such as
chromosomal aberrations and gene mutations observed in breast
tumors indicate that breast tumorigenesis does not follow a
stepwise linear progression from well-differentiated to poorly
differentiated tumors with cumulative genetic aberrations [4]. This
suggests that different breast tumor subtypes do not represent
different stages of tumor progression, but rather represent the cells
from which they initiate [4]. The mammary gland is composed of
differentiated luminal and myoepithelial cells that are generated
from multi-lineage, luminal-restricted, and myoepithelial-restrict-
ed progenitors originating from a hypothetical breast epithelial
stem cell. Thus, different types of breast cancers might originate
from such stem or progenitor cells at a given stage of commitment
and differentiation, as observed in hematological malignancies
[4,5]. Without compromising the author’s hypothesis, it is also
possible that the molecular heterogeneity of breast cancer is due to
subtle differences in the ability of tumor-initiating cells to generate
differentiated progeny.
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successive senescence states in cell culture, termed ‘‘stasis’’ and
‘‘agonescence’’ [6,7]. In contrast to normal mammary epithelial
cells, established breast cancer cells are immortal by definition.
They may owe this phenotype of immortalization to genetic and
epigenetic inactivation of senescence checkpoints and reactivation
of telomerase reverse transcriptase expression [7]. Either in
relation to these changes or independently, breast cancer cells
may also present a stem/progenitor phenotype that is less
subjected or resistant to senescence barriers. However, the
abundance of non-tumorigenic and differentiated cells both in
breast tumors and cell lines strongly suggests that replicative
immortality cannot be assigned to all cells within a tumor or a
cancer cell line, and that spontaneous senescence after a limited
number of population doublings (PD) is likely to occur. If this
hypothesis is correct, then the rate of generation of senescent
progeny may reflect the potential of a cancer stem/progenitor cell
to produce terminally differentiated progeny. We tested this
hypothesis using a panel of luminal and basal-like breast cancer
cell lines (Table S1). Although a single cell line is not representative
of breast tumor heterogeneity, a panel of cell lines might
reproduce the heterogeneity that is observed in primary breast
tumors, albeit with some limitations [5,8]. Therefore, we hoped
that in vitro studies with a panel of cell lines might help to better
understand breast tumor heterogeneity.
Our senescence tests allowed us to classify breast cancer cell
lines as senescent cell progenitor (SCP) and immortal cell
progenitor (ICP) subtypes. We also show that senescent progeny
are observed exclusively in ER-positive cells, as a result of ER
inactivation, partly mediated with p21
Cip1 protein. The ability to
produce senescent progeny was associated with the ability to
produce luminal-like and myoepithelial-like progeny from stem/
progenitor-like cells. In contrast, most of the cell lines lacking
senescent progeny were also unable to generate differentiated
progeny. Finally, we show that SCP-subtype cells cluster with
luminal A and ‘‘normal-like’’ breast tumor types and are less
tumorigenic, whereas ICP-subtype cell lines cluster with luminal B
and basal-like tumor types and are more tumorigenic.
Materials and Methods
Ethics Statement
We used archival tumor samples remaining from a previous
study by BB and IGY described in Gur-Dedeoglu et al. [9], for
which the use of the tissue material was approved by the Research
Ethics Committee of Ankara Numune Research and Teaching
Hospital (decision date: 04/07/2007). The tumor samples in this
study were used anonymously. All animals received care according
to the Guide for the Care and Use of Laboratory Animals. All
animal experiments have been pre-approved by the Bilkent
University Animal Ethics Committee (Decision No: 2006/1;
Decision date: 10/5/2006).
Clinical samples and cell lines
Freshly frozen tumor specimens were collected at Ankara
Numune Hospital. Breast cancer cell lines used in this study were
obtained from ATCC (http://www.atcc.org) and listed in Table
S1. Cell line authenticity was verified by short tandem repeat
profiling, as recommended by ATCC (Dataset S1). Isogenic clones
from the T47D (n=20) cell line were obtained from single cell-
derived colonies. Briefly, cells were plated in 96-well plates to
obtain single colonies in fewer than 70% of the wells. Isolated
colonies were then transferred to progressively larger wells, and to
T25 flasks. Clones were subcultivated weekly at 1:4 dilution ratios,
and maintained in culture for 25–30 passages to reach .60 PD
before testing.
Primary antibodies
The following antibodies were used: anti-CD44 (559046; BD
Pharmingen), anti-CD24 (sc53660; Santa Cruz,), anti-ASMA
(ab7817; Abcam), anti-CK19 (sc6278; Santa Cruz,), anti-p21
Cip1
(OP64; Calbiochem), anti-p16
Ink4a (NA29, Calbiochem), anti-ERa
(sc8002; Santa Cruz).
Low-density clonogenic assays
Cells were seeded as low-density on coverslips in six-well plates
(500–2000 cells, according to plating efficiency) and allowed to
grow in DMEM supplemented with 10% fetal calf serum (FCS),
with medium change every three days, until they formed colonies
of a few hundred cells. Depending on the cell line, this took one to
two weeks. For bromodeoxyuridine (BrdU) incorporation assays,
cells were labeled for 24 h prior to immunocytochemistry, as
described previously [10].
Immunocytochemistry
For simple immunoperoxidase assays, cells were fixed with cold
methanol for five minutes, then blocked with 10% FCS in
phosphate-buffered saline (PBS) for 1 hour. This was followed by
incubation with a primary antibody for 1 h. Cells were then washed
with PBS three times and subjected to immunostaining using the
Dako-Envision-dual-link system and the liquid diaminobenzidine
(DAB) substrate chromogen system (Dako, CA, USA), according to
the manufacturer’s instructions. Hematoxylin was used as a
counter-stain when the visualization of cells was necessary. For
SABG-immunoperoxidase co-staining studies, unfixed cells were
first subjected to SABG assay, and then fixed prior to immuno-
staining assays. Hematoxylin counter-staining was omitted for co-
staining experiments, unless cells were negative for SABG staining.
Immunoblot analyses
Cell pellets were incubated in an NP-40 lysis buffer containing
50 mM Tris–HCl, pH 8.0, 250 mM NaCl, 0.1% Nonidet P-40,
and a protease inhibitor cocktail (Roche) for 30 minutes in a cold
room. Cell lysates were then cleared by centrifugation, and a
Bradford assay was performed to quantify their protein concen-
tration. 30 mg of protein was denatured and resolved by SDS-
PAGE using 10% or 12% gels. The proteins were then transferred
to the PVDF or nitrocellulose membranes. Membranes were
treated for 1 h with a blocking solution of TRIS-buffered saline
containing 0.1% Tween-20 and 5% non-fat milk powder (TBS-T)
and probed with a primary antibody for 1 h. Next, membranes
were washed three times with TBS-T and incubated with an HRP-
conjugated secondary antibody for 1 h. Immunocomplexes were
then detected by an ECL-plus (Amersham) kit on the membrane.
a-tubulin was used as an internal control.
SABG assay and BrdU/SABG co-staining
SABG activity was detected as described [11], except that cells
were counterstained with eosin or nuclear fast red following SABG
staining. For BrdU/SABG co-staining, cells were first labeled with
BrdU (10 mg/ml) for 24 h in a freshly added culture medium as
described [10]. Next, cells were subjected to a SABG assay, fixed
in 70% methanol, and subjected to BrdU immunostaining.
Estrogen and tamoxifen treatment
Cells were seeded under low-density clonogenic conditions onto
coverslips in six-well plates, and cultivated in a standard culture
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red-free DMEM (Gibco) supplemented with 5% charcoal-stripped
FCS for 48 h, followed by two successive 48 h treatments with
10
29 M estrogen (E2; 17b-estradiol; Sigma), 10
26 to 10
29 M4 -
hydroxytamoxifen (4OHT; Sigma) or an ethanol vehicle, under
the same conditions. Colonies were then subjected to a SABG
assay. Each experimental condition was conducted in triplicate
and experiments were repeated three times.
Generation of estrogen receptor-overexpressing clones
T47D-iso23 cells were transfected with the expression vector
pCMV- ERa [12] or an empty vector, using FuGENE-6 (Roche).
ER overexpressing and control clones were selected with 500 mg/
ml G418 for three weeks. Isolated single cell-derived colonies were
picked and expanded in the presence of G418.
Lentiviral infection and generation of p21
Cip1 knockdown
clones
We used mission shRNA plasmid pLKO.1,-puro-p21
(NM_000389.2-640s1c1, Sigma) for p21
cip1 knockdown experi-
ments. The Control vector shRNA-pGIPz-SCR-puro and a helper
packaging mix (Invitrogen) were also used. HEK293T was co-
transfected with the appropriate vector and packaging mix, using
the CalPhos Mammalian Transfection Kit (Clontech) and
following the manufacturer’s instructions. After 48 h of culture,
virus-containing culture media were collected, filtered, and used to
infect T47D-iso23 cells. After 4 h of infection, stable cells were
selected with 1 mg/ml puromycin for seven days.
Nude mice tumorigenicity and in vivo senescence assays
T47D and MDA-MB-231 cells (5610
6) were injected subcuta-
neously into CD-1 nude mice (Charles River). Females (n=5 for
each cell line) and males (n=4 for each cell line) were used.
Tumor sizes were measured up to 47 days post-injection. In
addition, four tumors from each cell line were analyzed for the
presence of senescent cells by SABG staining, as described
previously [10].
Cluster analysis
The two-channel microarray data containing 8102 cDNA
genes/clones generated by Sorlie et al. [2] were downloaded from
the Stanford Microarray Database (SMD) (http://genome-www.
stanford.edu/MicroArray/). In the downloading process, the ‘‘log
(base 2) of R/G Normalized Ratio (median)’’ parameter was used
for data filtering. We have median-centered expression values for
each array. We selected arrays and genes with greater than 75%
good data (representing the amount of data passing the spot
criteria). Sixty-eight tissue samples were obtained according to this
criterion and annotated with the subtypes described by the
authors, found in the ‘‘Supplementary Information’’ of the data set
in SMD. The expression values of ‘‘500 gene signature,’’ defined
by the authors, were extracted from the data. Gene expression
profiles of 31 breast cancer cell lines performed by Charafe-
Jauffret et al. [13], using the whole-genome cDNA microarray
Affymetrix HGU-133 plus 2, was obtained from the ‘‘Supplemen-
tary Table’’ of the article. The authors filtered genes with low and
poorly measured expression, and with low expression variation,
retaining 15, 293 genes. After log transformation of the data, we
median normalized the data arrays in R language, using the
Bioconductor biostatistical package (www.r-project.org/ and
www.bioconductor.org/). The ‘‘500 gene signature’’ tumor data
[2] and the normalized breast-cancer cell line data [13] were
combined with respect to probe IDs using a set of customized perl
routines (source codes are available upon request). A set of 175
genes was common. ‘‘Median center’’ normalization of genes was
done for the merged data set for the total samples. We performed
unsupervised hierarchical clustering with the 99 samples (the 31
breast cell line [13] and 68 breast tumor [2] samples) by the pair-
wise complete-linkage hierarchical clustering parameter, using the
Gene-Pattern program. The Pearson correlation method was used
for distance measurements. Clustering was visualized by java
treeview, again using Gene-Pattern (http://www.broad.mit.edu/
cancer/software/genepattern/).
Statistical analyses
Significant differences were evaluated using unpaired Student’s
t test for compared samples sizes of 10 or higher. Otherwise, one-
tailed Fisher’s exact test was used with 262 tables; P,0.05 was
considered statistically significant. On the graphical representation
of the data, y-axis error bars indicate the standard deviation for
each point on the graph.
Results
Classification of breast cancer cell lines as senescent-cell
progenitor and immortal-cell progenitor subtypes
Clonogenic assays have been successfully used to test the
generation and self-renewal abilities of phenotypically distinct
progeny of mammary stem/progenitor cells [14]. We previously
applied this technique to test the ability of cancer cells to produce
progeny with replication-dependent senescence arrest [10]. Cells
were plated under low-density clonogenic conditions and cultivat-
ed for one to two weeks until individual cells performed eight to
ten PDs and generated isolated colonies composed of several
hundred cells. This method permits tracing progeny generated by
a few hundred cells under the same experimental conditions. We
explored a panel of 12 breast cancer cell lines, composed of
luminal (n=7) and basal (n=5) subtypes (Table S1). Cell lines
formed two groups, according to the presence of senescent cells in
isolated colonies. One group of cell lines generated colonies with
high rates of senescence, while others did not produce appreciable
amounts of senescent cells. Representative pictures of colonies
subjected to the SABG assay are shown in Fig. 1A. The percent of
SABG+ progeny was calculated by manual counting of at least 10
different colonies for each cell line. Colonies derived from five cell
lines generated SABG+ cells at high rates (means: 5-40%)
Senescence rates were negligible (means ,5%) in the progeny of
the remaining seven cell lines. The first group, the senescent cell
progenitor subtype, included T47D, BT-474, ZR-75-1, MCF-7,
and CAMA-1 cell lines. The second group, the immortal cell
progenitor subtype, included MDA-MB-453, BT-20, SK-BR-3,
MDA-MB-468, HCC1937, MDA-MB-231 and MDA-MB-157
(Fig. 1B).
In order to verify whether the occurrence of senescent cells in the
SCP group was intrinsic to each cell line or due to the presence of a
side population, we generated clones from the T47D (n=20) cell
line, and subjected them to the SABG assay at different intervals. All
clonesactedsimilarlytotheparentalT47Dcelllinewithsimilarrates
of SABG+ progeny. No clone gained the ICP phenotype. More
importantly, none of the clones tested over a long period of time
(.60 PDs) entered full senescence (data not shown), unlike normal
mammary epithelial cells that undergo two stages of senescence
arrest over a period of ,20 PDs [7]. The SABG assay can provide
false-positive responses, especially when cells remain under conflu-
ence for a long period [15]. Although all our tests used low-density
clonogenic conditions, we wanted to confirm the senescence arrest
by a long-term (24 h) BrdU labeling assay under mitogenic
Senescence in Breast Cancer
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incorporate BrdU under these conditions [16]. Co-staining of cells
for SABG and BrdU from CAMA-1, T47D, and T47D-iso23
colonies provided clear indication that the great majority of SABG+
senescent cells were BrdU-, whereasnon-senescent BrdU+ cells were
usually SABG- (Fig. 1C). These findings indicated that SABG+
senescent cells were at the terminal differentiation stage with an
irreversible loss of DNA synthesis ability. Our observations also
indicated that SABG and BrdU tests could be used alternatively to
identify senescent (SABG+/BrdU-) and immortal (SABG-/BrdU+)
cells under our experimental conditions.
Senescent cell progenitor phenotype association with
p21
Cip1 expression
p16
Ink4a and p21
Cip1 (in a p53-dependent manner or indepen-
dently) have been shown to be mediators of senescence arrest in
different cells, including mammary epithelial cells [6,15,17,18,19].
We therefore analyzed the expression of p16
Ink4a and p21
Cip1 in
the cell line panel. Heterogeneously positive nuclear p21
Cip1
immunoreactivity was observed in four of the five SCP cell lines,
but not in any of the seven ICP cell lines (Fig. 2A). The association
of p21
Cip1 expression with the SCP subtype was statistically
significant (P=0.01). We also compared the expression of p16
Ink4a.
Three of five SCP cell lines displayed heterogeneously positive
immunostaining, whereas three of seven ICP cell lines displayed
homogenously positive staining (Fig. S1). The difference of
p16
Ink4a expression between the two groups was not significant
(P=1). These observations indicated that the SCP phenotype was
associated with p21
Cip expression in breast cancer cell lines.
To test whether p21
Cip1 was directly involved in the senescence
observed in SCP cells, we first performed p21
Cip1/SABG staining
in T47D-iso23 cells (hereafter termed T47D). p21
Cip1, but not
p16
Ink4a staining, was associated with SABG staining (Fig. S2).
Next, we generated two derivative cell lines following infection of
T47D with lentiviral vectors encoding p21
Cip1 shRNA (T47D-
p21sh) or a scrambled control (T47D-scr). Following the
Figure 1. Classification of breast cancer cell lines as senescent cell progenitor and immortal cell progenitor subtypes. (A) Examples of
SABG staining for senescence of breast cancer cell line colonies obtained after plating at low-density clonogenic conditions. Breast cancer cell lines
(Table S1) were plated to obtain a few hundred colonies with 1–2 weeks of cell culturing and were subjected to SABG assay, followed by
counterstaining with nuclear fast red. T47D, ZR-75-1, MCF-7, CAMA-1 and BT-474 generated heterogeneous colonies composed of with SABG+ and
SABG- cells (shown here), but also fully negative and/or fully positive colonies. All other cell lines produced only SABG- colonies (,5% SABG+ cells).
Scale bar: 50 mm. (B) Classification of breast cancer cell lines as senescent cell progenitor (SCP) and immortal cell progenitor (ICP) subtypes by
quantification of the ability to generate senescent progeny. Cell lines with a mean of SABG+ cells higher than 5% were termed SCP, and the other cell
lines as ICP. Colonies that were generated and stained as described in (A) were counted manually to calculate % SABG+ cells. At least 10 colonies
were counted for each cell line. Error bars represent mean 6 SD. (C) SABG+ senescent cells displayed terminal growth arrest. CAMA-1, T47D and
T47D-iso23 colonies were generated as described in (A), labeled with BrdU for 24 h in the presence of freshly added culture medium, and subjected
to SABG/BrdU double-staining. SABG+ cells are BrdU-, and vice versa. T47D-iso23 is a clone derived from T47D. Note that parental T47D and T47D-
iso23 clones displayed similar staining features.
doi:10.1371/journal.pone.0011288.g001
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Cip1 knockdown in T47D-p21sh cells by
western blot assay (Fig. 2B), both cell lines were plated under low-
density plating conditions, colonies were grown for 10 days, and
subjected to SABG and BrdU staining. It was not possible to
quantify SABG+ cells in T47D-p21sh cells because they formed
tight clusters in culture (data not shown). We therefore used BrdU
staining as an alternative method for senescent cell quantification
(Fig. 2C). Randomly selected colonies were counted for the
number of BrdU+ and BrdU- cells (Fig. 2D). The T47D-scr cell
line generated BrdU+ progeny at a rate of 48620% per colony
(n=18). Under the same conditions, T47D-p21sh cells displayed
BrdU+ progeny at a rate of 65612% per colony (n=18), with a
significant (P=0.0043) increase in the number of cells escaping
terminal arrest (Fig. 2E). These results indicated that p21
Cip1 was
responsible, at least partly, for inducing the senescence observed in
the progeny of T47D cells.
The control of senescent cell progeny generation by an
estrogen receptor
As stated above, p21
Cip1 is a downstream target of p53 for
senescence, but T47D cells do not express wild-type p53 (Table S1).
Estrogen inhibits p21
Cip1 expression [20] by c-Myc-mediated
repression [21], MYC gene being a direct target of ER complex
[22]. We therefore tested whether ER could be involved in the
senescence observed in T47D cells. The data shown in Fig. 3A
indicates that T47D cells displayed nuclear ER immunoreactivity in
their great majority, but some progeny was ER-. More interestingly,
these ER- cells tended to be SABG+, suggesting that senescence
occurred in T47D cells as a result of ER loss. Next, we tested
whether experimentally modifying ER activity in T47D cells had
any effect on senescence response. After plating at low-density
clonogenic conditions, cells were grown in a regular cell culture
medium that contained weakly estrogenic phenol red [23] for seven
days in order to obtain visible colonies. The culture medium was
then changed with phenol-free DMEM complemented with
charcoal-treatedFCS,grownfortwo more days,andthencultivated
for four more days in the presence of E2 (10
29 M), OHT (10
29 M
to 10
26 M), or an ethanol vehicle as control. Colonies were
subjected to SABG staining (Fig. 3B). Total and SABG+ cells were
counted from 20 randomly selected colonies for each treatment
(Fig. 3C). Colonies grown in a phenol-free charcoal-treated control
medium complemented with an ethanol vehicle only displayed
31613% SABG+ cells. Complementing this medium with 10
29 M
Figure 2. Growth arrest observed in senescent cell progenitors was inhibited by p21
Cip1 silencing. (A) Four of five senescent SCP cell
lines (top four from left) generated colonies with heterogeneous expression of p21
Cip1; in contrast none of seven ICP cell lines generated p21
Cip1 cells.
Colonies were immunostained for p21
Cip1, with hematoxylin used as counterstain. Scale bar: 50 mm. (B–E) p21
Cip1 silencing inhibited the production
of the terminally arrested progeny of SCP cells. (B) shRNA-mediated inhibition of p21
Cip1 expression. T47D cells were infected with lentiviral vectors
encoding p21
Cip1 shRNA or scrambled shRNA to generate T47D-p21sh and T47D-scr stable cell lines, and tested for p21
Cip1 knockdown by western
blotting. (C–E) The ability to generate growth-arrested cells was inhibited by p21
Cip1 knockdown. Colonies were generated from respective cell lines,
labeled with BrdU for 24 h, immunostained for BrdU, and slightly counterstained with hematoxylin to visualize BrdU+ and negative cells. Scale bar:
50 mm. (C). Individual colonies were manually counted for quantification of % BrdU cells. Each bar represents one colony (D). The silencing of p21
Cip1
caused a significant increase (P=0.0043) in % ratios of BrdU+ cells (E). Mean % BrdU+ cells (6 SD) values were calculated from data presented in (D).
Error bars represent mean 6 SD. Tub.; a-tubulin.
doi:10.1371/journal.pone.0011288.g002
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inhibition by E2 was nearly 50% and statistically significant when
compared to the ethanol-complemented control cells (P=0.0093).
In contrast to E2, OHT provoked a dose-dependent increase in the
proportion of SABG+ cells. At the maximum dose used (10
26 M
OHT), 90613% of colony-forming cells displayed a SABG+ signal
(Fig. 3D), indicating that tamoxifen-mediated inactivation of ER
can induce almost a complete senescence response in these cells
(P,0.0001). The increase in senescence rate was also significant
with 10
27 MO H T( P=0.0002).
Our findings strongly suggested that the senescence observed in
the SCP T47D cell line was due to a loss of expression and/or
function of ER in a subpopulation of the progeny of these cells.
For confirmation, we constructed ER-overexpressing stable clones
from T47D cells. The thhree clones with the highest ER
expression were selected. In addition, three clones with endoge-
nous expressions of ER were selected from stable clones obtained
with an empty vector (Fig. 4A). Progeny obtained from these six
clones were tested by BrdU assay (Fig. S3). Randomly selected
colonies (n=10) from each clone were evaluated for total and
BrdU+ number of cells (Fig. 4B). Consistently higher levels of
BrdU+ cells were observed with clones ectopically expressing the
ER protein (Fig. 4C). Overexpression of ER resulted in a
significant increase in the BrdU+ progeny (P=0.034). The
protective effect of ER overexpression was not as important as
the senescence-promoting effects of ER inhibition. This was not
unexpected, since the parental cells used for the ER overexpres-
sion studies were already expressing high levels of endogenous ER
(Fig. 4A), displaying a baseline anti-senescence activity due to the
serum estrogen and phenol red found in the cell culture medium.
The close relationship between ER and senescence in the ER+
T47D cell line, and the highly effective treatment of ER+ breast
tumors with tamoxifen, which induced senescence in our
experimental model, suggested that senescence induction might
be a relevant mechanism involved in anti-estrogen treatments. As
fresh tumor tissues cannot be obtained from tamoxifen-treated
patients for obvious ethical reasons, we analyzed untreated ER+
breast tumor samples for evidence of spontaneously occurring in
vivo senescence. We screened a panel of 12 snap-frozen ER+
breast tumor tissues from 11 patients for senescence by an SABG
Figure 3. Generation of senescent cell progeny was controlled by the estrogen receptor-a. (A) SCP cells (T47D) expressed nuclear ER.
Colonies were co-stained for senescence by SABG and for ER expression by immunoperoxidase. The MDA-MB-231 cell line was used as a negative
control. (B–D) The production of senescent progeny in SCP cells was inhibited by estrogen (E2), but enhanced by tamoxifen (4OHT) treatment. After
plating in low-density clonogenic conditions, T47D cells were grown in standard cell culture medium for seven days, followed by phenol-free DMEM
complemented with charcoal-treated fetal calf serum for two days, and then cultivated for four days in the presence of E2, OHT, or an ethanol vehicle
(control). Colonies were subjected to SABG staining (B). Total and SABG+ and SABG- cells were counted from 20 randomly selected colonies (C), and
mean % SABG+ cells (6 SD) values were calculated (D). Error bars represent mean 6 SD. The inhibition of senescence by E2 and its activation by OHT
was statistically significant when compared to ethanol-complemented control cells (P values 0.0093, 0.0002 and ,0.0001 for 10
29 M E2, 10
27 M OHT
and 10
26 M OHT, respectively).
doi:10.1371/journal.pone.0011288.g003
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menopause status (Table S2). Two tumors (17%) displayed
SABG+ cells that were scattered within the tumor area (Fig. S4).
Thus, ER+ breast tumors also produced senescent progeny in vivo,
but at a lower rate.
Senescent cell progenitor and immortal cell progenitor
subtypes’ abilities to differentiate into luminal and
myoepithelial cell types
The cellular specificity of ER expression in the mammary
epithelial cell hierarchy is poorly understood. Previous data
suggests that normal ER+ cells may represent either relatively
differentiated luminal cells with limited progenitor capacity or
primitive progenitors with stem cell properties in the luminal cell
compartment [4,24,25]. Based on the close association between
senescence (which can be considered a manifestation of terminal
differentiation) and loss of ER positivity, we hypothesized that
ER+ SCP cells may differ from ER- ICP cells by their
differentiation potential. We surveyed a few hundred single-cell-
derived colonies from each of the 12 cell lines for production of
stem/progenitor-like, luminal-like, and myoepithelial-like cells.
We used CD44 as a positive stem/progenitor cell marker [26,27],
CD24, ER, and CK19 as luminal lineage markers [27,28,29], and
ASMA as a myoepithelial lineage marker [29].
Representative examples of marker studies by immunoperox-
idase staining in SCP and ICP cell lines are shown in Fig. 5. All
five SCP cell lines displayed a heterogeneous pattern of positivity
for CD44; some colonies were fully positive, some fully negative,
and others were composed of both positive and negative cells.
CD44/CD24 double immunofluorescence studies with the T47D
cell line indicated that SCP cells produce also CD44+/CD24-
stem/progenitor cells, as expected (data not shown). In sharp
contrast, five of the seven ICP cell lines generated only fully
positive CD44 colonies, indicating they do not produce CD44-
cells. One cell line was totally CD44-. Only one cell line displayed
Figure 4. Overexpression of estrogen receptor-a inhibited the production of terminally arrested progeny. (A) ER-overexpressing (ER-5,
ER-7, ER-26) and control (C-8, C-10, C-11) clones were established from T47D cells and tested for ER expression by western blotting using decreasing
amounts of total proteins. Calnexin was used as loading control. (B–C). Colonies were generated, labeled with BrdU for 24 h and immunostained for
BrdU (shown in Fig. S3). Individual colonies were manually counted for quantification of % BrdU cells (B), and mean % BrdU+ cells values were
calculated (C). Error bars represent mean 6 SD. ER overexpression caused a significant increase in % ratio of BrdU+ cells (*three ER clones versus three
controls; P=0.034).
doi:10.1371/journal.pone.0011288.g004
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subtypes indicated that the ability to generate both CD44+ and
CD44- progeny was significantly associated with the SCP
phenotype (P=0.0046). All five SCP cell lines displayed
heterogeneous, but mostly positive ER immunostaining, whereas
all seven ICP cell lines never generated ER+ cells. The expression
of ER was also significantly associated with the SCP subtype
(P=0.0012), as well as the ability to produce ASMA+ progeny
(P=0.0046). The ICP cell lines did not generate ASMA+ cells,
while four out of five SCP cell lines generated rare ASMA+ cells
under low-density clonogenic conditions. Interestingly, the abun-
dance of ASMA+ cells was much higher in the two SCP cell lines
that were tested at high cell density (Fig. S5). This suggests that
either the production of ASMA+ cells is enhanced at high cell
density, or these myoepithelial-like cells display limited survival
under long-term culture conditions. We did not find a strong
association between the expression of CD24 and CK19 markers
and cell subtype. All five SCP cell lines and three ICP cell lines
Figure 5. Senescent cell progenitor and immortal cell progenitor subtypes greatly differed in their ability to differentiate into
luminal and myoepithelial lineage cells. Senescent cell progenitor and immortal cell progenitor subtype cell lines were studied by
immunoperoxidase staining using CD44 and markers for luminal epithelial (CD24, CK19, ER) and myoepithelial (ASMA) lineages. Insets: magnified
views of positive cells. Both subtypes have CD44+ cells. Senescent cell progenitor cell lines produced both progenitor-like (CD44+; CD242), as well as
ER+ luminal-like and ASMA+ myoepithelial-like cells (except ZR-75-1 for myoepithelial-like cells). Immortal cell progenitor cell lines were defective for
generation of ER+ luminal-like or ASMA+ myoepithelial-like cells. Moreover, five of seven cell lines could not generate CD44- cells. The expression of
CD24 and CK19 markers did not differ significantly between the two subgroups, except that some immortal cell progenitor subtype cell lines did not
express CD24 or CK19.
doi:10.1371/journal.pone.0011288.g005
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Similarly, all five SCP cell lines, as well as three ICP cell lines,
expressed CK19, but homogenously.
Typical features of senescent progenitor and immortal
progenitor breast cancer cell lines
As summarized in Fig. 6, SCP and ICP subtype cell lines
displayed several subtype-specific features. All SCP cell lines
produced differentiated and senescent cells, in addition to putative
CD44+/CD242 stem/progenitor cells. Indeed, all of them
produced ER+ and CD24+ luminal-like cells and most of them
(n=4/5) also produced ASMA+ myoepithelial-like cells. In
contrast, five of the seven ICP cell lines never produced CD44-
cells, suggesting they cannot generate differentiated progeny under
the experimental conditions tested. In confirmation of this
hypothesis, four ICP cell lines only produced CD44+/CD242/
ER-/CK19-/ASMA- stem/progenitor-like, but never differentiat-
ed cells. Furthermore, all seven ICP cell lines were unable to
produce ASMA+ myoepithelial-like, ER+ luminal-like or SABG+
senescent cells. CD24 and CD19 luminal lineage markers were
expressed in three cell lines, one of which was fully positive for the
CD44 stem/progenitor marker.
SCP and ICP subtype cell lines correlate with distinct
breast tumor subtypes
Distinct cell-type features associated with SCP and ICP subtypes
suggest that they may be phenocopies of molecularly defined
breast tumor subtypes [1,2,3,30]. As the prognosis and therapeutic
response of each subtype is different [2,3], we questioned whether
we could assign SCP and ICP cell lines to known molecular
subtypes of breast tumors. Using cell line and primary tumor gene
expression datasets, we conducted a hierarchical clustering
analysis. The ‘‘intrinsic gene set’’ data generated by Sorlie et al.
[2] to classify breast tumors into five molecular subtypes was used
to filter cell line data generated by Charafe-Jauffret et al. [13]. A
set of 175 genes was common between the two data sets. Sixty-
eight tumors and 31 cell lines were subjected to pair-wise
complete-linkage hierarchical clustering and distance measure-
ments. This tumor–cell line combined analysis produced two
major clusters. One cluster was composed of basal and luminal B
subtype tumors and five of six ICP cell lines. The other cluster
included luminal A, ERBB2+, and ‘‘normal-like’’ subtype tumors
and all five SCP subtype cells. Four cell lines clustered with the
luminal A tumor subclass. Finally. one cell line clustered with the
‘‘normal-like’’ subclass (Fig. 7A). A full list of clustered tumors and
cell lines is provided in Fig. S6.
Luminal A tumors clustering with our SCP subtype cell lines
displayed the longest tumor-free, distant metastasis-free, and
overall survival rates. In contrast, basal and luminal B tumors
clustering with our ICP subtype cell lines had the worst prognosis,
with shorter tumor-free, distant metastasis-free, and overall
survival times [2]. Our cluster analysis suggested that the ability
to generate differentiated and senescent progeny characterized
breast cancers with poor tumorigenicity, and that resistance to
differentiation and senescence was indicative of more aggressive
tumorigenicity. We compared in vivo intrinsic tumorigenic
behaviors of the SCP cell line T47D and the ICP cell line
MDA-MB-231 in female (n=5 for each cell line) and male (n=4
for each cell line) CD1 nude mice Fig. 7B). MDA-MB-231 cells
displayed higher tumorigenicity than T47D cells. In total, we
observed progressively growing tumors in five of nine animals
injected with MDA-MB-231. In contrast, T47D formed smaller
and regressing tumors in nine of nine animals (P,0.03).
Interestingly, the difference in tumorigenicity between these two
cell lines was more pronounced in male animals (P,0.05 after 20
days post-injection). To test whether the difference in tumorige-
nicity between MDA-MB-231 and T47D cells was correlated with
spontaneous in vivo senescence, we analyzed four tumors from
each cell line. Two T47D tumors displayed positive SABG
staining, whereas no positive staining was observed with all four
MDA-MB-231 tumors (Fig. S7).
Discussion
In recent years, phenotypic heterogeneity of breast cancers has
been correlated with genetic and molecular heterogeneity [1,3].
Breast cancer subtypes may represent cancers originating from
different progenitor cells. Molecular and phenotypic heterogeneity
and associated clinical manifestations of breast tumor subtypes
have been related to the type of hypothetical tumor progenitor
cells originating from a hypothetical mammary epithelial stem cell
or from downstream progenitor cells [4,5]. This hypothesis has
not been fully validated, mainly because a hierarchical map of
cells involved in mammary epitheliogenesis has not yet been
established.
To better understand phenotypic differences between breast
cancer subtypes, we applied senescence as a surrogate marker for
the potential to generate terminally differentiated progeny. We
completed these studies with markers for breast stem/progenitor
and differentiated luminal and myoepithelial lineage cells. The use
of low-density clonogenic conditions allowed us to follow the fate
Figure 6. Typical features of senescent progenitor and
immortal progenitor breast cancer cell lines.
doi:10.1371/journal.pone.0011288.g006
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approaches, we draw several important conclusions. First, breast
cancer cell lines form two distinct groups: SCP and ICP subtypes.
The SCP cell lines produce non-senescent and senescent progeny,
whereas the ICP cell lines produce only non-senescent progeny.
Second, SCP and ICP cell lines are exclusively ER+ and ER- cell
lines, respectively. Senescence occurs as a result of ER loss
associated with p21
Cip1 induction in SCP cells. Inversely,
experimental activation of ER by E2 protects from senescence,
whereas its inactivation by tamoxifen aggravates it. Thus,
senescence in ER-dependent cells appears to result from the loss
of survival signals generated by transcriptional activity of ER. A
similar type of senescence has been reported for lymphoma,
osteosarcoma, and hepatocellular carcinoma tumors upon c-MYC
inactivation [31]. Third, SCP cells generate ER+, CD24+,o r
CK19+ luminal-like, as well as ASMA+ myoepithelial-like
progeny. These findings strongly suggest that most, if not all,
SCP cells have the capacity to give rise to two major types of
differentiated cells that are found in normal mammary epithelium.
In sharp contrast, ICP cells never produce ER+ luminal-like or
Figure 7. Senescence cell progenitor and immortal cell progenitor subtype cell lines correlate with distinct breast tumor subtypes.
(A) Unsupervised hierarchical clustering of breast tumor and cell line gene expression data were obtained from Sorlie et al [2] and Charafe-Jauffret et
al [25]. Dendrogram displaying the relative organization of tumor and cell line data demonstrated that ICP cell lines cluster with basal and luminal A
tumors in the same branch, except for MDA-MB-453. In contrast, SCP cell lines clustered with luminal A (BT-474, CAMA-1, MCF-7, T47D) and ‘‘normal-
like’’ tumors (ZR-75-1). No data was available for MDA-MB-468. A dendrogram with sample IDs was provided in Fig. S6. The ‘‘intrinsic gene set’’ data
generated by Sorlie et al. [2] was used to filter cell line data generated by Charafe-Jauffret et al. [13]. A set of 175 genes was common between the
two data sets. Sixty-eight tumors and 31 cell lines were subjected to pair-wise complete-linkage hierarchical clustering and distance measurements.
(B) Immortal cell progenitor MDA-MB-231 was more tumorigenic than the SCP type T47D cell line. Female (n=5 per cell line) and male (n=4 per cell
line) CD1nude mice received 5610
6 cells by subcutaneous injection and observed up to 47 days for tumor formation. Chart displays mean tumor sizes
(6 S.D.) generated by MDA-MB-231 and T47D cell lines, respectively in female (top) and mala (bottom) mice. T47D cells formed smaller tumors that
regressed and completely resolved within 30 days. Tumors formed by MDA-MB-231 were larger in size and did not show total resolution. Note that
this cell line was more tumorigenic in male mice.
doi:10.1371/journal.pone.0011288.g007
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only CD44+ stem/progenitor-like cells and never CD442,
CD24+, CK19+,E R +, or ASMA+ cells. These findings indicate
that ICP cells have limited differentiation ability, at least under in
vitro conditions. The differentiation ability of ICP cells appears to
be lost completely or partially, so that they do not differentiate
fully while they self-renew as stem/progenitor-like cells. Fourth,
SCP cell lines form the same molecular cluster with luminal A and
‘‘normal-like’’ breast tumors. This suggests that SCP cell lines are
phenocopies of these relatively benign and/or anti-estrogen-
responsive tumors. The poor tumorigenicity of SCP cells in nude
mice correlates with better tumor-free and metastasis-free survival
of patients with luminal A type tumors. In contrast, ICP cell lines
cluster with luminal B and basal-like breast tumor subtypes, and
they are more tumorigenic, as expected for luminal B and basal-
like tumor cells. It is presently unknown whether breast tumor
subtypes that cluster with SCP or ICP cell lines are also composed
of either differentiating or mostly self-renewing stem/progenitor
cells. Recent studies reported that breast tumors may contain only
CD44+, or only CD24+ cells, as well as mixed cell populations,
and that CD44+ tumor cells express many stem-cell markers
[27,32]. In addition, an association between basal-like breast
cancer and the presence of CD44+/CD242 cells has been
established [32].
The mechanisms of the differentiation block observed in ICP
cell lines are not known. One might argue that cell lines that
produce only CD44+, but never differentiation marker-positive
cells, cannot be defined as stem/progenitor cells. However, such
cell lines are not completely inert to differentiation stimuli, and
may undergo differentiation under special conditions. For
example, MDA-MB-231 and MDA-MB-468 cells (identified as
ICP cell lines here) can be induced to differentiate into ER+ cells
by Wnt5a treatment, and MDA-MB-231 cells then become
sensitive to tamoxifen [33].
Most of the findings reported here are derived from in vitro
studies performed with established cancer cell lines. Presently, it is
unknown to what extent these findings are also relevant for breast
tumors. We provide here some promising data that supports in
vivo relevance of our conclusions. First, our cluster analyses
associated SCP cell types with luminal A and ‘‘normal-like’’ breast
tumors, whereas ICP cell types shared similar gene expression
profiles with luminal B and basal-like breast tumors. Second, ICP-
type MDA-MB-231 cells were more tumorigenic than SCP-type
T47D cells. T47D cells formed smaller tumors in some animals,
and all tumors displayed regression between 10 and 15 days post-
injection. Accordingly, we observed positive SABG staining in two
out of four T47D tumors, but not in MDA-MB-231 tumors.
Obviously, ICP-like and SCP-like tumors in affected women may
or may not display similar tumorigenic potentials, depending on
the women’s hormonal status and treatment conditions. However,
as most SCP-like luminal A or ER+ tumors are successfully treated
with tamoxifen [34], their less aggressive behavior could be related
to their highly effective senescence response to tamoxifen
treatment, as shown here with T47D cells under in vitro
conditions (Fig. 3). It will be interesting to examine whether the
success of anti-estrogenic treatments is indeed associated with
senescence induction in breast tumors. If this is the case,
senescence-inducing treatments could be considered for breast
cancer.
In conclusion, our analyses reveal that the in vitro ability to
generate senescent progeny permits discrimination between cells
that share molecular and tumorigenic similarities with luminal A
subtype breast tumors from cells related to basal/luminal B
subtype tumors. We also provide in vitro evidence for classifying
breast cancers into two major groups based on the ability to
generate differentiated progeny. Less-tumorigenic SCP cell lines
generate both luminal- and myoepithelial-like cells. In contrast,
more-tumorigenic ICP cell lines are defective in their ability to
generate differentiated progeny. Our findings may have prognostic
relevance and serve as a basis for therapeutically inducing
differentiation and senescence in breast cancer.
Supporting Information
Dataset S1 STR analysis data that shows the authenticity of
breast cancer cell lines used in this study.
Found at: doi:10.1371/journal.pone.0011288.s001 (1.50 MB
XLS)
Table S1 Gene clusters, genetic mutations and epigenetic
changes of breast cancer cell lines used in this study.
Found at: doi:10.1371/journal.pone.0011288.s002 (0.05 MB
DOC)
Table S2 Estrogen receptor (ER) status, main pathological
features of senescence staining (SABG) of breast tumors used in
this study.
Found at: doi:10.1371/journal.pone.0011288.s003 (0.05 MB
DOC)
Figure S1 p16Ink4a expression in colonies obtained from breast
cancer cell lines. There was no correlation between p16Ink4a
expression and progenitor subtype.
Found at: doi:10.1371/journal.pone.0011288.s004 (3.39 MB TIF)
Figure S2 Co-staining experiments indicate that SABG staining
is associated with p21Cip1, but with p16Ink4a expression in SCP
cells. Colonies were generated from T47D and MB-MDA-231
cells and subjected to SABG staining, followed by p21Cip1 or
p16Ink4a immunoperoxidase (brown) staining. MDA-MB-231
cells were used as negative control.
Found at: doi:10.1371/journal.pone.0011288.s005 (2.74 MB TIF)
Figure S3 Effect of estrogen receptor-overexpression on the
production of BrdU-negative terminally arrested cell progeny. ER-
overexpressing (ER-5, ER-7, ER-26) and control (C-8, C-10, C-
11) stable clones were established from T47D cells. Following
transfection with ER expression and control vectors, colonies were
generated from respective cell lines, labeled with BrdU for 24 h,
immunostained for BrdU (brown), and slightly counterstained with
hematoxylin to visualize BrdU+ and BrdU- cells.
Found at: doi:10.1371/journal.pone.0011288.s006 (6.57 MB TIF)
Figure S4 Detection of SABG+ senescent cells in estrogen
receptor-positive breast tumors. Snap-frozen tumors were used to
obtain 6 m thick sections and used directly to detect SABG+ cells.
H&E: hematoxylin-eosin staining.
Found at: doi:10.1371/journal.pone.0011288.s007 (9.45 MB TIF)
Figure S5 ASMA+ myoepithelial-like cells are produced fre-
quently in senescent cell progenitor T47D and MCF-7 cell lines
under confluent conditions. ASMA was tested by immunoperox-
idase.
Found at: doi:10.1371/journal.pone.0011288.s008 (4.08 MB TIF)
Figure S6 Unsupervised hierarchical clustering of breast tumor
and cell line gene expression data that is described in Fig. 7A.
Dendrogram shown here includes tumor and cell line sample IDs.
Found at: doi:10.1371/journal.pone.0011288.s009 (1.05 MB TIF)
Figure S7 Tumors derived from T47D but not from MDA-MB-
231 display SABG (+) senescent cells. Two of four T47D tumors
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SABG+ cells.
Found at: doi:10.1371/journal.pone.0011288.s010 (7.97 MB TIF)
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